Agenus prioritizes resources to accelerate registration and commercialization of bot/bal program in multiple cancers

Lexington, mass.--(business wire)--agenus inc. (“agenus”) (nasdaq: agen), a pioneer in immuno-oncology, today announced a strategic initiative to prioritize and focus resources to accelerate the development, registration, and commercialization of its flagship program botensilimab/balstilimab (bot/bal). under this new plan, agenus will temporarily postpone all preclinical and clinical programs not related to bot/bal. the plan will result in a workforce reduction of approximately 25% and deliver.
AGEN Ratings Summary
AGEN Quant Ranking